Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

Pfizer shares were rising early Tuesday after the company reported fourth-quarter earnings and revenue that came in ahead of ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Pfizer's Super Bowl ad received mixed reactions on social media, but many criticized the pharma giant for saying it will ...

BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

The Food and Drug Administration expanded its approval of one of Pfizer's drugs, Adcetris, allowing it to be used as a treatment for certain types of lymphoma.

Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with ...

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...